Holen Sie sich die Stockscreener-App
91.29
4.70%
-4.07
Schlusskurs vom Vortag:
$95.36
Offen:
$91.595
24-Stunden-Volumen:
787.23K
Relative Volume:
0.71
Marktkapitalisierung:
$9.79B
Einnahmen:
$769.10M
Nettoeinkommen (Verlust:
$46.67M
KGV:
260.83
EPS:
0.35
Netto-Cashflow:
$119.79M
1W Leistung:
-0.76%
1M Leistung:
+4.07%
6M Leistung:
+96.61%
1J Leistung:
+33.07%
1-Tages-Spanne:
$90.12
$93.35
1-Wochen-Bereich:
$90.12
$97.63
52-Wochen-Spanne:
$28.66
$97.63
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
91.21 | 10.24B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
479.82 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.66 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
894.46 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.97 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
280.76 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2026-03-26 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Wolfe Research downgrades Corcept stock on valuation concerns By Investing.com - Investing.com Canada
Corcept Therapeutics (CORT) Lifted Earnings Outlook, Is The Stock Now Overvalued? - Yahoo Finance UK
Corcept Therapeutics (CORT) Is Up 5.3% After Analysts Lift Full-Year Earnings Outlook Significantly - Yahoo Finance UK
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CORT|Corcept Therapeutics Inc|Price:95.330|Chg%:-1.330 - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corcept Therapeutics Inc (CORT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
WDC: Western Digital Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Corcept Therapeutics Inc (CORT) Fundamental & Financial Data - Stocktwits
CORT: Corcept Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Corcept Therapeutics And 2 Other Growth Stocks With Significant Insider Ownership - simplywall.st
Corcept Therapeutics to announce Q2 results on July 29 - scanx.trade
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Corcept Therapeutics stock hits 52-week high at 95.18 USD By Investing.com - Investing.com Canada
Trump Disclosure Shows Corcept Buy Before FDA Approval - Moomoo
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Corcept Therapeutics(CORT.US) Officer Sells US$3.51 Million in Common Stock - Moomoo
Corcept Therapeutics CFO Mokari sells $3.5m in shares By Investing.com - Investing.com South Africa
Corcept Therapeutics CFO Mokari sells $3.5m in shares - Investing.com
Corcept Therapeutics director Wilson sells $882,985 in common stock By Investing.com - Investing.com UK
Form 4 Corcept Therapeutics Incorporated For: 17 July By Investing.com - Investing.com Canada
Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan - Stock Titan
Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options - Stock Titan
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook - Yahoo Finance
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook - The Motley Fool
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup - ChartMill
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case - Law360
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors - Seeking Alpha
Corcept Therapeutics : CORT - 24/7 Wall St.
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com - Investing.com Nigeria
Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings - Stock Titan
Corcept Therapeutics CDO William Guyer sells $1.86m in stock - Investing.com
Corcept Therapeutics CDO William Guyer sells $1.86m in stock By Investing.com - Investing.com India
Insider at Corcept (NASDAQ: CORT) sells shares after option exercise - Stock Titan
Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise - Stock Titan
Corcept Therapeutics highlights its endocrine focus as investors watch CORT stock - AD HOC NEWS
CORT News | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept (CORT) executive sells 25K shares after exercising options - Stock Titan
CORTCorcept Therapeutics Inc Options - Finviz
Corcept Therapeutics stock hits 52-week high at 91.1 USD By Investing.com - Investing.com Canada
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report - Sahm
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to book forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):